These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38482511)

  • 21. Effect of nabiximols oromucosal spray (Sativex
    Garde N; Heibel M
    Drugs Context; 2024; 13():. PubMed ID: 38384931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A
    Chisari CG; Guadagno J; Adjamian P; Vila Silvan C; Greco T; Bagul M; Patti F
    Ther Adv Neurol Disord; 2023; 16():17562864231195513. PubMed ID: 37745913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of specialist nurses in detecting spasticity and related symptoms in multiple sclerosis.
    Artola M; Hernando A; Vidal O; Vidal N; Cuenca E; Horno R; Robles MÁ; Oriol C; Peralta S; Solana MAJ; Rubio M; Montero C; Lleixà M; Zabay C; Martin M; Leon I; Molinos C; Matamoros M; Mercadé L; Fornali O; Montero L; Saiz A; Solà-Valls N
    J Clin Nurs; 2023 Jul; 32(13-14):3496-3503. PubMed ID: 35799407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience.
    Sartori A; Dinoto A; Stragapede L; Mazzon G; Morelli ME; Pasquin F; Bratina A; Bosco A; Manganotti P
    Neurol Sci; 2021 Dec; 42(12):5037-5043. PubMed ID: 33742336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and treatment of spasticity reported by multiple sclerosis patients.
    Rizzo MA; Hadjimichael OC; Preiningerova J; Vollmer TL
    Mult Scler; 2004 Oct; 10(5):589-95. PubMed ID: 15471378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis.
    Carod-Artal FJ; Adjamian P; Vila Silván C; Bagul M; Gasperini C
    Expert Rev Neurother; 2022 Jun; 22(6):499-511. PubMed ID: 35582858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-identified factors that influence spasticity in people with stroke and multiple sclerosis receiving botulinum toxin injection treatments.
    Cheung J; Rancourt A; Di Poce S; Levine A; Hoang J; Ismail F; Boulias C; Phadke CP
    Physiother Can; 2015; 67(2):157-66. PubMed ID: 25931667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spasticity-Plus syndrome in multiple sclerosis patients in a tertiary hospital in Spain.
    Goicochea Briceño H; Higueras Y; Ruiz Pérez I; García Domínguez JM; Cuello JP; Meldaña Rivera A; Martínez Ginés ML
    Front Neurol; 2024; 15():1360032. PubMed ID: 38469589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.
    Pozzilli C
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):49-54. PubMed ID: 24289844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described 'spasticity-plus syndrome'.
    Patti F; Chisari CG; Fernández Ó; Sarroca J; Ferrer-Picón E; Hernández Vicente F; Vila Silván C
    Eur J Neurol; 2022 Sep; 29(9):2744-2753. PubMed ID: 35590453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Management of symptoms associated with spasticity in patients with multiple sclerosis].
    Fernández-Pablos MA; Costa-Frossard L; García-Hernández C; García-Montes I; Escutia-Roig M;
    Enferm Clin; 2016; 26(6):367-373. PubMed ID: 27492746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
    Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.
    Zajicek J; Fox P; Sanders H; Wright D; Vickery J; Nunn A; Thompson A;
    Lancet; 2003 Nov; 362(9395):1517-26. PubMed ID: 14615106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intrathecal Versus Oral Baclofen: A Matched Cohort Study of Spasticity, Pain, Sleep, Fatigue, and Quality of Life.
    McCormick ZL; Chu SK; Binler D; Neudorf D; Mathur SN; Lee J; Marciniak C
    PM R; 2016 Jun; 8(6):553-62. PubMed ID: 26498518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Broad Concept of "Spasticity-Plus Syndrome" in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms.
    Fernández Ó; Costa-Frossard L; Martínez-Ginés M; Montero P; Prieto JM; Ramió L
    Front Neurol; 2020; 11():152. PubMed ID: 32256440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathophysiology, assessment and management of multiple sclerosis spasticity: an update.
    Haas J
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):3-8. PubMed ID: 21449853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.
    Trojano M; Celius EG; Donzé C; Izquierdo G; Patti F; Pöhlau D
    Eur Neurol; 2014; 72 Suppl 1():15-9. PubMed ID: 25278119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity.
    Paul F; Silván CV
    Neurodegener Dis Manag; 2021 Apr; 11(2):143-153. PubMed ID: 33641348
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.